 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Rallybio participates in a conference call with JPMorgan

Rallybio presents Phase 1 single ascending dose data for RLYB116

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare...

Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 2023...

Rallybio to Present at Upcoming Investor Conferences in September

Rallybio (NASDAQ:RLYB  Free Report) had its target price hoisted by JPMorgan Chase  Co. from $17.00 to $18.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an overweight rating on the stock. RLYB has been the subject of a number of ...

JPMorgan Chase & Co. Raises Rallybio (NASDAQ:RLYB) Price Target to $18.00

Rallybio Co. (NASDAQ:RLYB  Free Report)  Research analysts at HC Wainwright upped their Q3 2023 EPS estimates for shares of Rallybio in a report released on Wednesday, August 9th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.49) for...

Q3 2023 EPS Estimates for Rallybio Co. (NASDAQ:RLYB) Boosted by Analyst

Rallybio Co. (NASDAQ:RLYB Free Report) Equities researchers at Wedbush raised their Q3 2023 EPS estimates for shares of Rallybio in a research note issued on Tuesday, August 8th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.54) for the quarter, up from ...

Wedbush Weighs in on Rallybio Co.'s Q3 2023 Earnings (NASDAQ:RLYB)

Rallybio (NASDAQ:RLYB  Get Free Report) had its price objective lifted by equities researchers at JPMorgan Chase  Co. from $17.00 to $18.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an overweight rating on the stock. JPMorgan Chase...

Rallybio (NASDAQ:RLYB) PT Raised to $18.00 at JPMorgan Chase & Co.

Latest Ratings for RLYB
 DateFirmActionFromTo Feb 2022JMP SecuritiesInitiates Coverage OnMarket Outperform Aug 2021Evercore ISI GroupInitiates Coverage OnOutperform Aug 2021Cowen & Co.Initiates Coverage OnOutperform
 View More Analyst Ratings for RLYB

 View the Latest Analyst Ratings

read more...

Analyst Ratings for Rallybio

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Watchers	104
52-Wk Low	$3.30
52-Wk High	$14.93

Market Cap	$127.39M
Volume (M)	55,941.00
52-Wk High	$14.93
52-Wk Low	$3.30

RLYB Rallybio Corp

About

Feed

News

Earnings

Fundamentals